Free tool
FAERS Monitor: Sandimmune
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050625 or its brand name (Sandimmune, Cyclosporine). Reports on generic versions are filed under their own applications.
Reports
59,541
Serious
54,174
91% of reports
Hospitalization
18,811
Death reported
11,541
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective7,900
- off label use7,898
- product use in unapproved indication3,645
- pyrexia2,998
- diarrhoea2,325
- condition aggravated2,180
- nausea2,123
- pneumonia2,085
- cytomegalovirus infection2,033
- hypertension1,802
- sepsis1,776
- fatigue1,767
- rash1,689
- headache1,668
- graft versus host disease1,635
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,059 |
| 2005 | 1,096 |
| 2006 | 1,185 |
| 2007 | 1,149 |
| 2008 | 1,939 |
| 2009 | 2,161 |
| 2010 | 1,898 |
| 2011 | 2,565 |
| 2012 | 1,719 |
| 2013 | 758 |
| 2014 | 878 |
| 2015 | 861 |
| 2016 | 1,005 |
| 2017 | 1,285 |
| 2018 | 1,812 |
| 2019 | 2,498 |
| 2020 | 3,621 |
| 2021 | 3,670 |
| 2022 | 5,359 |
| 2023 | 5,487 |
| 2024 | 6,906 |
| 2025 | 6,085 |
| 2026 | 4,539 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,994,618 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| graft versus host diseaseSignal | 1,635 | 103.6 | 98.1 | 128,402 |
| cytomegalovirus infectionSignal | 2,033 | 49.1 | 46.9 | 84,089 |
| sepsisSignal | 1,776 | 5.7 | 5.4 | 6,804 |
| product use in unapproved indicationSignal | 3,645 | 5.3 | 5.1 | 12,527 |
| off label useSignal | 7,898 | 3.2 | 3.1 | 12,395 |
| pyrexiaSignal | 2,998 | 3.1 | 3.0 | 4,239 |
| hypertensionSignal | 1,802 | 3.0 | 2.9 | 2,441 |
| condition aggravatedSignal | 2,180 | 2.5 | 2.4 | 2,056 |
| pneumoniaSignal | 2,085 | 2.3 | 2.2 | 1,516 |
| drug ineffectiveSignal | 7,900 | 2.1 | 2.1 | 4,983 |
| rash | 1,689 | 1.4 | 1.3 | 171 |
| diarrhoea | 2,325 | 1.3 | 1.2 | 140 |
| nausea | 2,123 | 0.9 | 0.9 | 6 |
| headache | 1,668 | 0.9 | 0.9 | 7 |
| fatigue | 1,767 | 0.8 | 0.8 | 90 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.